Referencias bibliográficas

1. Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021 Jan;17(1):37-51. [Pubmed]
2. Kamminga S, van der Meijden E, Feltkamp MCW, Zaaijer HL. Seroprevalence of fourteen human polyomaviruses determined in blood donors. PLoS One. 2018 Oct 23;13(10):e0206273. [Pubmed]
3. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009 Mar 15;199(6):837-46. [Pubmed]
4. Moens U, Krumbholz A, Ehlers B, Zell R, Johne R, Calvignac-Spencer S, Lauber C. Biology, evolution, and medical importance of polyomaviruses: An update. Infect Genet Evol. 2017 Oct;54:18-38. [Pubmed]
5. Lauver MD, Lukacher AE. JCPyV VP1 Mutations in Progressive MultifocalLeukoencephalopathy: Altering Tropismor Mediating Immune Evasion? Viruses. 2020 Oct 12;12(10):1156. [Pubmed]
6. Pietropaolo V, Prezioso C, Bagnato F, Antonelli G. John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy. New Microbiol. 2018 Jul;41(3):179-86. [Pubmed]
7. White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy--revisited. J Infect Dis. 2011 Mar 1;203(5):578-86. [Pubmed]
8. Pavlovic D, Patel MA, Patera AC, Peterson I; Progressive Multifocal Leukoencephalopathy Consortium. T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. Immunobiology. 2018 Jun-Jul;223(6-7):508-17. [Pubmed]
9. Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013 Apr 9;80(15):1430-8. [Pubmed]
10. Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012 Nov;72(5):779-87. [Pubmed]
11. Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol. 2014 Oct;1(10):755-64. [Pubmed]
12. Chatterton S, Dwyer L, Thomson C, Plit M, Longmuir H, Chaganti J, et al. Atypical presentations and course of JC virus infection. J Neurovirol. 2022 Jan 9. Epub ahead of print. [Pubmed]
13. Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2013 Dec;19(14):1826-40. [Pubmed]
14. Morgello S, Cho ES, Nielsen S, Devinsky O, Petito CK. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of the literature. Hum Pathol. 1987 Mar;18(3):289-97. [Pubmed]
15. Möhn N, Grote-Levi L, Hopfner F, Eiz-Vesper B, Maecker-Kolhoff B, Warnke C, et al. Innovative therapeutic concepts of progressive multifocal leukoencephalopathy. J Neurol. 2022 Jan 7. Epub ahead of print. [Pubmed]
16. Clifford DB, Nath A, Cinque P, Brew BJ, Zivadinov R, Gorelik L, et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol. 2013 Aug;19(4):351-8. [Pubmed]
17. De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J, et al.; Gesida 9/99, IRINA, ACTG 363 Study Groups. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS. 2008 Sep 12;22(14):1759-67. [Pubmed]
18. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med. 1998 May 7;338(19):1345-51. [Pubmed]
19. Jamilloux Y, Kerever S, Ferry T, Broussolle C, Honnorat J, Sève P. Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. Clin Drug Investig. 2016 Oct;36(10):783-9. [Pubmed]
20. Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, et al.; Italian PML study group. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017 Mar 21;88(12):1144-52. [Pubmed]
21. Mahler C, Andrews M, Henson SM, Gnanapavan S. Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm. 2020 May 20;7(4):e756. [Pubmed]
22. Dubey D, Zhang Y, Graves D, DeSena AD, Frohman E, Greenberg B. Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. Ther Adv Neurol Disord. 2016 May;9(3):211-5. [Pubmed]
23. Beck ES, Cortese I. Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. Curr Opin Virol. 2020 Feb;40:19-27. [Pubmed]
24. Berzero G, Basso S, Stoppini L, Palermo A, Pichiecchio A, Paoletti M, et al. Adoptive Transfer of JC Virus-Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy. Ann Neurol. 2021 Apr;89(4):769-79. [Pubmed]
25. Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, et al. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2021 Nov 15;360:577721. [Pubmed]
26. Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, et al.; OFSEP Investigators. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. JAMA Neurol. 2020 Jan 1;77(1):94-102. [Pubmed]
27. Villar LM, Costa-Frossard L, Masterman T, Fernández O, Montalbán X, Casanova B, et al. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol. 2015 Mar;77(3):447-57. [Pubmed]
28. Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019 Oct 8;93(15):e1452-e1462. [Pubmed]